PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Holdings Lifted by ProShare Advisors LLC

ProShare Advisors LLC increased its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 32.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,102 shares of the biopharmaceutical company's stock after purchasing an additional 6,164 shares during the period. ProShare Advisors LLC's holdings in PTC Therapeutics were worth $1,133,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in PTCT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in PTC Therapeutics by 0.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 65,681 shares of the biopharmaceutical company's stock valued at $2,967,000 after buying an additional 205 shares during the period. Arizona State Retirement System increased its position in PTC Therapeutics by 1.1% during the fourth quarter. Arizona State Retirement System now owns 20,095 shares of the biopharmaceutical company's stock worth $907,000 after purchasing an additional 219 shares during the last quarter. Choreo LLC increased its position in PTC Therapeutics by 2.0% during the fourth quarter. Choreo LLC now owns 11,961 shares of the biopharmaceutical company's stock worth $541,000 after purchasing an additional 240 shares during the last quarter. Summit Investment Advisors Inc. raised its stake in PTC Therapeutics by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,968 shares of the biopharmaceutical company's stock worth $360,000 after purchasing an additional 253 shares during the period. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of PTC Therapeutics by 78.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 613 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 270 shares during the last quarter.

Insider Buying and Selling

In other news, Director Allan Steven Jacobson sold 1,230 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $51.52, for a total value of $63,369.60. Following the completion of the sale, the director now owns 19,118 shares of the company's stock, valued at approximately $984,959.36. The trade was a 6.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Stephanie Okey sold 5,000 shares of PTC Therapeutics stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $54.00, for a total value of $270,000.00. Following the completion of the transaction, the director now owns 8,867 shares of the company's stock, valued at $478,818. This trade represents a 36.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,264 shares of company stock worth $1,469,137. Insiders own 5.50% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on PTCT shares. Wall Street Zen downgraded PTC Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 16th. Morgan Stanley restated an "overweight" rating and set a $70.00 price target (up from $67.00) on shares of PTC Therapeutics in a research note on Friday, March 7th. Barclays reduced their price objective on PTC Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 8th. Wells Fargo & Company increased their target price on shares of PTC Therapeutics from $68.00 to $74.00 and gave the stock an "overweight" rating in a research report on Tuesday. Finally, Cantor Fitzgerald cut their price target on shares of PTC Therapeutics from $113.00 to $112.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. One analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $63.75.

PTC Therapeutics Trading Down 0.3%

PTCT stock traded down $0.12 during trading on Wednesday, reaching $47.74. The stock had a trading volume of 97,477 shares, compared to its average volume of 858,368. The firm has a fifty day moving average price of $46.99 and a 200 day moving average price of $47.43. The company has a market capitalization of $3.78 billion, a P/E ratio of -8.03 and a beta of 0.52. PTC Therapeutics, Inc. has a 1-year low of $28.72 and a 1-year high of $58.38.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $9.19. The business had revenue of $1.18 billion during the quarter, compared to analysts' expectations of $437.16 million. The company's revenue for the quarter was down 9.6% on a year-over-year basis. During the same period in the prior year, the company posted ($1.20) EPS. Sell-side analysts predict that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

PTC Therapeutics Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.